Travere Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q3 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Travere Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2010 to Q3 2024.
  • Travere Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$54.8M, a 136% decline year-over-year.
  • Travere Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$351M, a 304% decline year-over-year.
  • Travere Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$111M, a 60% increase from 2022.
  • Travere Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$278M, a 54.6% decline from 2021.
  • Travere Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$180M, a 6.29% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$351M -$54.8M -$206M -136% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 -$146M -$70.4M +$15.2M +17.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$161M -$136M -$49.7M -57.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 -$111M -$90.2M -$24.4M -37% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 -$87M $151M +$220M Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 -$307M -$85.6M -$18.6M -27.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$289M -$86.3M -$10.4M -13.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 -$278M -$65.8M -$14.3M -27.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 -$264M -$69.7M -$34M -95.4% Jul 1, 2022 Sep 30, 2022 10-K 2024-02-20
Q2 2022 -$230M -$67M -$28M -71.8% Apr 1, 2022 Jun 30, 2022 10-K 2024-02-20
Q1 2022 -$202M -$76M -$22.1M -41% Jan 1, 2022 Mar 31, 2022 10-K 2024-02-20
Q4 2021 -$180M -$51.6M +$70M +57.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 -$250M -$35.6M -$13.1M -58.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 -$237M -$39M -$12.9M -49.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$224M -$53.9M -$54.7M -6767% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$169M -$122M -$91.4M -302% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 -$78.1M -$22.5M +$13.9M +38.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-29
Q2 2020 -$92M -$26.1M +$12.6M +32.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 -$105M $808K +$41.8M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$146M -$30.3M -$22.8M -306% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$124M -$36.5M +$18M +33.1% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$142M -$38.7M -$16.4M -73.3% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$125M -$41M -$22.6M -123% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 -$103M -$7.46M +$10.2M +57.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-24
Q3 2018 -$113M -$54.5M -$36.7M -206% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-24
Q2 2018 -$76.1M -$22.3M -$9.1M -68.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-24
Q1 2018 -$67M -$18.4M -$7.29M -65.7% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-24
Q4 2017 -$59.7M -$17.6M -$9.02M -105% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-26
Q3 2017 -$50.7M -$17.8M +$19.3M +52.1% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-26
Q2 2017 -$70M -$13.2M +$174K +1.3% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-26
Q1 2017 -$70.2M -$11.1M -$22.3M -199% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-26
Q4 2016 -$47.9M -$8.6M -$6.13M -248% Oct 1, 2016 Dec 31, 2016 10-K/A 2018-07-06
Q3 2016 -$41.8M -$37.1M -$143M -135% Jul 1, 2016 Sep 30, 2016 10-K/A 2018-07-06
Q2 2016 $101M -$13.4M +$12.1M +47.5% Apr 1, 2016 Jun 30, 2016 10-K/A 2018-07-06
Q1 2016 $88.8M $11.2M -$28.4M -71.7% Jan 1, 2016 Mar 31, 2016 10-K/A 2018-07-06
Q4 2015 $117M -$2.47M +$26.6M +91.5% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-01
Q3 2015 $90.7M $106M +$124M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-01
Q2 2015 -$32.9M -$25.5M -$37.3M -316% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-01
Q1 2015 $4.45M $39.7M +$115M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-01
Q4 2014 -$111M -$29M -$16.2M -126% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-26
Q3 2014 -$94.7M -$18M -$5.97M -49.7% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-26
Q2 2014 -$88.8M $11.8M +$16.7M Apr 1, 2014 Jun 30, 2014 10-K 2016-02-26
Q1 2014 -$105M -$75.7M -$70.9M -1456% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-26
Q4 2013 -$34.6M -$12.8M -$12.8M Oct 2, 2013 Dec 31, 2013 10-K 2015-03-11
Q3 2013 -$21.8M -$12M -$3.53M -41.6% Jul 1, 2013 Sep 30, 2013 10-Q/A 2015-07-09
Q2 2013 -$18.3M -$4.92M -$163K -3.43% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-11
Q1 2013 -$18.1M -$4.87M -$1.3M -36.3% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-11
Q4 2012 -$16.8M -$3.66K* -$143 Sep 1, 2012 Nov 30, 2012 10-Q 2013-03-06
Q3 2012 -$16.8M -$8.48M -$8.48M Jul 1, 2012 Sep 30, 2012 10-Q/A 2015-07-09
Q2 2012 -$8.34M -$4.76M -$4.76M Apr 1, 2012 Jun 30, 2012 10-Q 2013-09-16
Q1 2012 -$3.58M -$3.57M Jan 1, 2012 Mar 31, 2012 10-Q/A 2013-09-16
Q4 2011 -$3.52K* +$2.15K Sep 1, 2011 Nov 30, 2011 10-Q 2013-03-06
Q3 2011 -$3.53K* +$3.1K Jun 1, 2011 Aug 31, 2011 10-Q 2012-10-10
Q2 2011 -$3.52K* Mar 1, 2011 May 31, 2011 10-Q 2012-08-08
Q4 2010 -$5.67K* Sep 1, 2010 Nov 30, 2010 10-Q 2012-01-11
Q3 2010 -$6.63K* Jun 1, 2010 Aug 31, 2010 10-Q/A 2012-06-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.